Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Name | Sonwu Supply OEM Capsules Raw Powder Lapatinib Ditosylate |
CAS NO. | 388082-78-8 |
Molecular Formula | C12h17cln2s |
MW | 925.46 |
Purity | 99% |
Appearanc | White Powder |
Certificate | ISO, SGS, GMP, HACCP |
MOQ | 10 g |
Shelf life | 2 Years |
Lapatinib is a targeted therapy of breast cancer drug, is a tyrosine kinase inhibitor, can effectively inhibit the human epidermal growth factor receptor -1 (ErbB1) and human epidermal growth factor receptor (ErbB2) tyrosine kinase activity of -2. It is unique in that it can play a role in a variety of ways, so that breast cancer cells can not receive the signal needed for growth. The mechanism of action is to inhibit the intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites to prevent phosphorylation and activation of tumor cells, and to block the down-regulation of signaling by EGFR (ErbB-1) and HER2 (ErbB-1) homogeneous and heterogeneous two aggregates.
Molecular targeted therapy for breast cancer is the treatment of oncogenes and related expression products related
to the occurrence and development of breast cancer. Molecular targeted drugs control cell gene expression by
blocking the signal transduction of tumor cells or related cells, thereby inhibiting or killing tumor cells.
You may interested in:
Other Hot-Selling Similar Product | |||
Gefitinib | Lapatinib | AZD9291 | Niraparib |
Dasatinib | Imatinib | Ibrutinib | Niraparib tosylate monohydrate |
LOXO 195 | LOXO 101 | Fluconazole | Cabozantinib Malate |
baricitinib | ketoconazole | Imatinib mesylate | Erlotinib Hydrochloride |